Rating Rationale

Brickwork Ratings has assigned the long-term and short-term ratings at "BWR BBB/Stable" and "BWR A3" for the bank loan facilities of Rs. 100.82 Crores of Vamsi Labs Ltd.

The ratings assigned for the bank facilities of Vamsi Labs Ltd. continue to drive strength from experienced management, achievable profitability, and moderate financial risk profile of the company and BWR has relied upon the Audited FY 24, FY 25 and Provisionals of FY 26.

The rating outlook has been assigned as "Stable" as BWR believes that Vamsi Labs Ltd. business risk profile will be maintained over the medium term.

The 'Stable'' outlook indicates a low likelihood of rating change over the medium term.

The rating outlook may be revised to 'Positive' in case the revenue and profitability margins show sustained improvement.

The rating outlook may be revised to 'Negative' if the financial risk profile goes down.

The terms of sanction include standard covenants normally stipulated for such facilities.

• Management Experience : :

  Vamsi Labs Ltd was incorporated in 1991, with over 35 years of experience in manufacturing Active Pharmaceutical Ingredients (APIs) in India. The factory is located in MIDC area, Chincholi, Solapur, Maharashtra. The company is promoted by M Kesava Reddy (Chairman and Managing Director) who has around 40+ years of experience in the industry and Mrs.Pramiladevi.

• Moderate Financial Profile: : :

  The company has achieved a Sales of Rs.166.06 Crores in FY25 Audited. The TNW of the company stood at Rs. 93.03 Crores in FY25 strengthening the capital base and Total Debt/TNW, ISCR and DSCR of the company stood at 1.07 times, 4.82 times and 1.49 times in FY25 Audited. Brickwork Ratings expects the revenue to sustain at similar levels in the near-to-medium term because of stable demand in the pharmaceutical industry.

• Regulatory and Quality Hurdles : :

  The Indian pharmaceutical industry operates under stringent regulatory and quality norms, including GMP guidelines, CDSCO regulations, and international standards such as USFDA and EU GMP. Compliance with these regulations requires continuous investment in quality systems, documentation, skilled manpower, and plant upgrades, leading to higher operating costs. Any non-compliance may result in regulatory observations, warning letters, product recalls, or temporary shutdowns, which can disrupt operations and impact revenues.

• Price Pressure and Government Policies : :

  The Indian pharmaceutical industry faces significant price pressures due to intense competition and government regulations. Policies by the National Pharmaceutical Pricing Authority (NPPA) cap prices of essential drugs, which can limit revenues and compress profit margins. Frequent changes in healthcare schemes and reimbursement policies create uncertainty in demand, making business planning challenging. Companies must carefully balance regulatory compliance with profitability, and sustained government intervention may impact investment, R&D, and expansion plans, especially for smaller players.

• Critical Supply Chain Vulnerabilities : :

  Many companies rely heavily on imported raw materials, especially active pharmaceutical ingredients (APIs) from countries like China, which creates risks during geopolitical tensions or global crises like pandemics. Poor infrastructure in rural areas makes it difficult to distribute medicines effectively, leading to shortages in some regions. Additionally, vaccines and biologic drugs require strict temperature-controlled storage, known as a cold chain, which can be hard to maintain in certain parts of the country. These factors together make supply chain management a significant challenge for the industry.

Going forward, the ability of the company to improve its revenue and financial risk profile would remain the key rating sensitivities.
Positive:

• Improvement in company's revenue by 30% and achieving a net profit margin by 5% or more along with enhanced cash accruals as against the proposed repayment obligation and a stronger cash and cash equivalents position.
• An improvement in the Current Ratio above 1.33 times, and maintaining debt protection metrics are at a comfortable level.

Negative:

• A decline in revenue by 20% along with decline in EBITDA and PAT margin below the current levels.
• A decline in the Current ratio below 1.00 times and DSCR below 1x times.

Adequate liquidity characterized by sufficient cushion in accruals vis-a-vis repayment obligations and moderate cash balance of Rs. 0.83 Crore. No Capex is envisaged in the near future. Its bank limits are utilized to the extent of 82% and has sought enhancement in bank lines, supported by the above unity current ratio.

The company had net cash accruals of Rs. 25.97 Cr as against a CPLTD of Rs. 15.95 Cr in FY2025.. Consequently, the Total Debt/TNW is 1.07 times. ISCR stood at 4.82 times in FY2025, indicating the company’s strong capacity to meet its interest.The company's EBITDA stood at Rs. 36.17 Crores in FY25 (audited financials) against interest and finance charges of Rs. 7.50 Crores. The EBITDA level remained more than adequate to service the interest obligations year on year. However, the company's Net Cash Accruals stood at Rs. 13.86 Crores as against the CPLTD of Rs. 18.54 Crores as per FY 26 Provisionals and DSCR and Current Ratio stood at 0.80 times and 1.04 times in FY26 Provisionals. Hence, the liquidity of the company is considered as stretched.

The company demonstrates a Adequate ESG profile based on its environmental, social, and governance practices.

Environmental: Environmental risks are driven by high water usage, waste generation, and reliance on energy-intensive processes, making disclosures on water consumption, waste-management practices, renewable energy share and emissions levels particularly important.

Social: Social factors hinge on adherence to labor laws, accident prevention frameworks, and human-capital development, with metrics such as workforce mix, safety performance , and training initiatives offering insights into operational resilience.

Governance: Governance assessment focuses on board independence, committee effectiveness, and robustness of compliance systems, supported by readily available disclosures on board structure, audit mechanisms, and risk-management practices.

Vamsi Labs Ltd was incorporated in 1991, with over 35 years of experience in manufacturing Active Pharmaceutical Ingredients (APIs) in India. The factory is located in MIDC area, Chincholi, Solapur, Maharashtra. The company is promoted by M Kesava Reddy (Chairman and Managing Director) who has around 40+ years of experience in the industry and Mrs.Pramiladevi.

Vamsi Labs has become a popular name for API's in India and is well known for Anti-asthma APis all over the world.Vamsi Labs is a fast growing pharmaceutical company, managed by technocrats. All the products are manufactured in 7 Production Buildings with 17 production lines. There are 180 reactors, sizes varying from 5 Ltr to 10 KL. Thermic fluid heating, high vacuum distillation, reactions up to 10 kg pressure and -70°C to 300°C temperature are possible. The quality management system is supported by testing, quality assurance and regulatory teams to meet the ever changing demands of the customers. The facility is approved by USFDA and EU GMP. There are 4 micronizers to micronize the APis to meet customer specific PSD requirements.

R&D is focused on development and commercialization of APis, intermediates and speciality chemicals, and on optimisation of the resources. Vamsi Labs is committed to comply with all applicable environmental laws and regulations. The high COD effluent is passed through multiple effect evaporator. The condensate from MEE is subjected to biological treatment, passed through RO and the outcome is reused in the plant under ZLD (Zero Liquid Discharge). 

The Complexity Indicator refers to the ease with which the returns associated with the rated instrument could be estimated. It does not indicate the risk related to the timely payments on the instrument, which is rather indicated by the instrument's credit rating. It also does not indicate the complexity associated with analysing an entity's financial, business, industry risks or complexity related to the structural,transactional or legal aspects. Details on the complexity levels of the instruments are available on BWR's website Complexity Levels.

Creadit Rating Agency	Status and Reason for Non-Cooparation	Date of Press Release
IND	In the absence of adequate information by the company	07Sep2026

Nil

BWR Board of Directors have no influence over rating decisions, nor do they sit on the rating committee or review, discuss or evaluate any credit rating during the Board meetings.

Brickwork Ratings (BWR), a Securities and Exchange Board of India [SEBI] registered Credit Rating Agency and accredited by Reserve Bank of India [RBI]. BWR is the 5th agency to get a credit rating registration in India in 2009 and its corporate office in Bengaluru. It has a country-wide presence with representatives in 150+ locations. Canara bank is an institutional investor in Brickwork.

Brickwork offers credit ratings of Bank Loan, Non- convertible / convertible / partially convertible debentures and other capital market instruments and bonds, Commercial Paper, perpetual bonds, asset-backed and mortgage-backed securities, partial guarantees and other structured / credit enhanced debt instruments, Security Receipts, Securitisation Products, Municipal Bonds, etc. BWR has also rated NGOs, Educational Institutions, Hospitals, Urban Local Bodies and Municipal Corporations.

Nature of Ratings & Information: BWR ratings are opinions on the relative ability of an entity/instrument to meet its financial obligations and are based on information obtained from issuers and other sources believed to be reliable. BWR does not conduct audits, due diligence, or independent verification of such information and does not guarantee its accuracy, adequacy, or completeness.Ratings are current only as of the date of publication and may be revised based on new or unavailable information.

No Advice or Recommendation: Ratings, reports, and related communications are not investment advice and do not constitute recommendations to buy, sell, or hold securities, or to sanction, renew, or disburse credit facilities. They do not represent offers or solicitations for any transaction. Users must rely on their own independent judgment and professional advice. Access to or use of these materials does not create any client relationship with BWR.

Liability, Usage & Regulatory Framework: This content is published for the purpose of dissemination of information as required under applicable laws and regulations. BWR holds exclusive copyright over the content. It may be used with appropriate credit to BWR, provided that the content is not altered or modified in any way that could change its meaning or intent. BWR retains the exclusive right to distribute or share its rating rationales, directly or indirectly, through any print, digital, or electronic media. All reports are provided on an "as is" basis without warranties of any kind, express or implied, including but not limited to merchantability, fitness for a particular purpose, or non-infringement. BWR and its affiliates shall not be liable for any direct, indirect, incidental, or consequential losses or damages arising from the use of these reports. Ratings are subject to continuous surveillance and may be revised, suspended, or withdrawn at any time without notice. These reports are intended for use within India only. BWR operates under SEBI Regulations and Code of Conduct.

For more information on policies and ratings, please visit our www.brickworkratings.com